Evidence map›Paper›PMID 33671266›Full record

ArticleCancers2021

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX.

Charlotte I Stroes, Sandor Schokker, Remco J Molenaar, Ron A A Mathôt, Maarten F Bijlsma, Stephanie O van der Woude, João P Belo Pereira, Gerrit K J Hooijer, Rob H A Verhoeven, Annemieke Cats and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Charlotte I StroesCancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-8976-6843
Sandor SchokkerCancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0003-3180-7790
Remco J MolenaarCancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-5651-3997
Ron A A MathôtDepartment of Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-8401-0879
Maarten F BijlsmaCancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Stephanie O van der WoudeCancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
João P Belo PereiraDepartment of Vascular Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Gerrit K J HooijerDepartment of Pathology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-8993-7101
Rob H A VerhoevenDepartment of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.
Annemieke CatsThe Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Department of Gastrointestinal Oncology, 1066 CX Amsterdam, The Netherlands.
Cecile GrootscholtenThe Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Department of Gastrointestinal Oncology, 1066 CX Amsterdam, The Netherlands.
Johanna W van SandickDepartment of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
Geert-Jan CreemersDepartment of Medical Oncology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.
Grard A P NieuwenhuijzenDepartment of Surgery, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.
Nadia Haj MohammadUniversity Medical Center Utrecht, Department of Clinical Oncology, Utrecht University, 3584 CX Utrecht, The Netherlands.
Jelle P RuurdaUniversity Medical Center Utrecht, Department of Surgery, 3584 CX Utrecht, The Netherlands.ORCID 0000-0001-6584-1677
Sybren L MeijerDepartment of Pathology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Maarten C C M HulshofDepartment of Radiation Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Mark I van Berge HenegouwenDepartment of Surgery, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-8689-3134
Hanneke W M van LaarhovenCancer Center Amsterdam, Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLThe Netherlands Cancer Institute · NLRadboud University Nijmegen · NLNetherlands Comprehensive Cancer Organisation · NLOncode Institute · NLUniversity Medical Center Utrecht · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the feasibility of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy. Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m

Indexed as

adjuvant chemotherapyesophageal adenocarcinomaoxaliplatinpredictive biomarkersproteomicsS-1S-1 pharmacokinetics

Identifiers

PMID33671266
PMCPMC7922275
OpenAlexW3130299334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.